2D cell culture market seen reaching $8.44B by 2030

By AI, Created 11:08 AM UTC, May 20, 2026, /AGP/ – The 2D cell culture market is projected to grow from $5.3 billion in 2025 to $5.83 billion in 2026 and reach $8.44 billion by 2030, according to The Business Research Company. The report points to personalized medicine, automation, and drug development demand as the main growth drivers, with North America leading and Asia-Pacific set to grow fastest.

Why it matters: - The 2D cell culture market sits at the center of biomedical research, drug development and safety testing. - Strong growth in the market signals continued demand for low-cost, reproducible lab models even as 3D cell culture gains ground. - Personalized medicine and biopharmaceutical pipelines are pushing more researchers to use patient-specific and high-throughput cell analysis.

What happened: - The Business Research Company said the 2D cell culture market will rise from $5.3 billion in 2025 to $5.83 billion in 2026. - The report projects the market will reach $8.44 billion by 2030. - The forecast implies a 10.0% CAGR from 2025 to 2026 and a 9.7% CAGR through 2030. - The report was released May 6, 2026. - The report covers market size, share, regional dynamics and product trends. - A free sample of the report is available.

The details: - 2D cell culture grows cells as a single layer on flat surfaces such as glass or plastic. - The format is used to study cellular behavior, biological mechanisms and drug responses. - Monolayer culture techniques, early-stage drug discovery, affordable plasticware, academic research use and standardized lab protocols supported past growth. - Future growth is expected to come from automated imaging systems, biopharmaceutical development, toxicology and safety testing, regenerative medicine research and continued use alongside 3D models. - The report points to wider adoption of standardized cell culture consumables, automated 2D culture platforms, high-reproducibility assays, high-throughput screening and cost-effective cell-based research. - Personalized medicine is a major demand driver because it depends on cultivating and analyzing patient-specific cells. - The Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also includes South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The report suggests 2D cell culture is not being displaced quickly by newer formats because it remains cheaper, standardized and deeply embedded in current workflows. - Automation and imaging are becoming more important as labs try to improve throughput and reproducibility. - The regional split points to a mature market in North America and a faster-expanding research and manufacturing base in Asia-Pacific.

What’s next: - The market is expected to keep expanding through 2030 as drug discovery, toxicology testing and regenerative medicine demand more cell-based research. - The company also highlighted related reports on cell cultures, cell culture media and 3D cell culture technologies. - More information is available in the full report.